ligelizumab

Novartis Ends Phase III Peanut Allergy Trial in Another Flop for Potential Xolair Successor
BioSpace
Thu, 01/18/24 - 10:58 am
Novartis
clinical trials
peanut allergy
ligelizumab
Blow for Novartis as ligelizumab can’t top Xolair in phase 3
Pharmaforum
Mon, 12/20/21 - 11:01 am
Novartis
ligelizumab
clinical trials
chronic spontaneous urticaria
Xolair
Oncology the focus for big pharma catalysts
EP Vantage
Tue, 09/28/21 - 11:19 am
Big Pharma
cancer
oncology
Merck
Keytruda
AbbVie
Vraylar
Gilead Sciences
Trodelvy
Sanofi
Sarclisa
Novartis
ligelizumab
Novartis gets FDA breakthrough therapy status for ligelizumab to treat chronic spontaneous urticaria
Pharmaceutical Business Review
Fri, 01/15/21 - 09:49 am
Novartis
breakthrough therapy
FDA
ligelizumab
chronic spontaneous urticaria
Novartis' ligelizumab outperforms Roche's Xolair in chronic urticaria clearance
Pharmafile
Wed, 10/9/19 - 11:10 pm
Novartis
clinical trials
ligelizumab
Roche
Xolair
chronic urticaria
Novartis, aiming to protect blockbuster sales, advances Xolair follow-up to phase 3
Fierce Pharma
Thu, 12/6/18 - 12:55 pm
Novartis
Xolair
ligelizumab
hives
clinical trials
Novartis plots to retain hives patients with monoclonal antibody that outshines Xolair
Endpoints
Tue, 12/4/18 - 09:43 am
Novartis
hives
monoclonal antibodies
ligelizumab
clinical trials